Publications by authors named "M Plazzi"
With advances in antiretroviral therapy for HIV treatment, newer drug combinations provide improved efficacy, safety, and compliance. This study evaluates switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) in a cohort of people living with HIV (PLWH). this Italian retrospective study included 426 PLWH who switched from rilpivirine (RPV)/TDF/emtricitabine (FTC) to DOR/3TC/TDF.
View Article and Find Full Text PDFObjectives: The aim was to investigate whether switching from EFV/F/TDF to B/F/TAF may improve neuropsychiatrc symptoms and neurocognition.
Design: Pilot, single-arm, prospective study of persons with HIV (PWH) on the efficacy and safety of switching from EFV/F/TDF to B/F/TAF.
Methods: Participants underwent neuropsychological assessment (NPA) at switch (T0) and after 48 weeks (T1).
Background: A rapid ART initiation approach can be beneficial in people with advanced HIV disease, in consideration of their high morbidity and mortality. The aim of our study was to evaluate the feasibility, efficacy and safety of rapid ART start with BIC/FTC/TAF in this setting.
Methods: Pilot, single-centre, single-arm, prospective, phase IV clinical trial conducted in a tertiary Italian hospital.
Sarilumab plus standard of care standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
EClinicalMedicine
March 2023
Background: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety of sarilumab in severe COVID-19.
Methods: In this phase 3, open-labeled, randomized clinical trial, conducted at 5 Italian hospitals, adults with severe COVID-19 pneumonia (excluding mechanically ventilated) were randomized 2:1 to receive intravenous sarilumab (400 mg, repeatable after 12 h) standard of care (SOC) (arm A) or to continue SOC (arm B).
Article Synopsis
- Development of new vaccines for SARS-CoV-2 aims to improve availability in low-income areas, despite existing effective vaccines.
- A study tracked immune responses in young and old volunteers after receiving the GRAd-COV2 vaccine, showing strong antibody and T-cell responses that were maintained for 3 months but declined by 6 months.
- GRAd-COV2 demonstrated good safety and immune response, making it a promising candidate for further clinical development as part of the COVID-19 vaccination strategy.